GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

FP-1039   Click here for help

GtoPdb Ligand ID: 11581

Synonyms: FGFR1:Fc | FP1039 | GSK-3052230 | GSK3052230 | HGS1036
Compound class: Peptide
Comment: FP-1039 (GSK3052230) is a fusion protein that comprises the extracellular domain of FGF receptor 1c (FGFR1c; to act as a trap for FGF ligands) fused with the Fc region of IgG1. The full peptide sequence is not disclosed in the primary citation [1]. FP-1039 is an oncology lead candidate [1,3].
No information available.
Summary of Clinical Use Click here for help
FP-1039 was progressed into clinical evaluation by Five Prime Therapeutics.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01244438 Study of FP-1039 in Subjects With Endometrial Cancers Phase 2 Interventional Five Prime Therapeutics, Inc. This study was terminated because no patients with endometrial cancers with qualifying FGFR2-specific mutations could be recruited.
NCT01868022 Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling Phase 1 Interventional GlaxoSmithKline 2